
NASDAQHealthcareBiotechnology
Latest quote
$17.58
−$0.96 · -5.18%
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Previous close
$17.58
−$0.96 · -5.18%
Regular session · ET · Market data may be delayed.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Day range
Current $17.58
52-week range
Current $17.58
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
65
Bullish
Risk
62
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Day range
Current $17.58
52-week range
Current $17.58
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 812.03M USD | 412.26M USD | 306.13M USD | 258.49M USD |
| Cost of goods sold | 272.87M USD | 233.48M USD | 216.82M USD | 178.46M USD |
| Gross profit | 539.17M USD | 178.78M USD | 89.31M USD | 80.02M USD |
| Research and development | 45.31M USD | 113.92M USD | 116.88M USD | 101.27M USD |
| Selling, general, and administrative | 392.47M USD | 321.86M USD | 291.48M USD | 294.51M USD |
| Operating expenses | 494.06M USD | 435.9M USD | 408.86M USD | 395.78M USD |
| Interest income | 16.5M USD | 7.12M USD | 11.26M USD | 947K USD |
| Interest expense | 56.85M USD | 50.03M USD | 31.61M USD | 26.68M USD |
| Depreciation and amortization | 22.62M USD | 48.91M USD | 49M USD | 48.25M USD |
| Operating income | 45.11M USD | −257.12M USD | −319.55M USD | −315.76M USD |
| Net income | −537.96M USD | −281.89M USD | −341.42M USD | −320.83M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$34.00
93.40% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI110.33M0.01%689.3B USD0.03%$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB97.91M0.05%78.7B USD0.03%$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK54.79M0.13%22.5B USD0.05%$298.35-3.85%
Vanguard Extended Market ETFVXF49.55M0.05%30.2B USD0.05%$211.44-3.21%
iShares Biotechnology ETFIBB17.31M0.17%10.53B USD0.44%$199.54-2.05%
First Trust Health Care AlphaDEX FundFXH15.43M1.38%1.11B USD0.61%$128.9-1.20%
Schwab U.S. Small-Cap ETFSCHA12.29M0.06%20.45B USD0.03%$30.51-2.83%
iShares Russell Mid-Cap Growth ETFIWP10.93M0.07%16.37B USD0.23%$116.81-4.32%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
First Trust Health Care AlphaDEX FundFXH
Schwab U.S. Small-Cap ETFSCHA
iShares Russell Mid-Cap Growth ETFIWPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.